IMMUPHARMA PLC LS-01
Research IMMUPHARMA PLC LS-01 (25I) on Bullrun: market cap EUR 23.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker25I
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 23.40M
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 1.81M
- Free cash flow-GBP 2.37M
Valuation Snapshot
latest market cap is EUR 23.40M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 1.81M | -GBP 2.37M | n/a | 0 | GBP 1.35M | n/a | GBP 686.86K |
| FY2024 | GBP 0 | -GBP 2.48M | -GBP 1.77M | n/a | -0.01 | GBP 236.90K | n/a | -GBP 542.86K |
| FY2023 | GBP 0 | -GBP 2.92M | -GBP 1.36M | n/a | -0.01 | GBP 208.48K | GBP 0 | GBP 1.06M |
| FY2022 | GBP 0 | -GBP 3.81M | -GBP 2.45M | n/a | -0.01 | GBP 667.81K | GBP 111 | GBP 2.52M |
| FY2021 | GBP 118.35K | -GBP 8.17M | -GBP 4.88M | n/a | -0.03 | GBP 1.65M | GBP 700 | GBP 4.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 23.40M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About IMMUPHARMA PLC LS-01
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is IMMUPHARMA PLC LS-01's market cap?
IMMUPHARMA PLC LS-01's market capitalization is EUR 23.40M.
What does IMMUPHARMA PLC LS-01 do?
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally.